title: [Analyzing of prognosis of intestinal T-cell lymphoma].
abstract: OBJECTIVE
  To investigate the roles of different clinicopathological features and expression of EBV genome in prognosis of intestinal T-cell lymphoma (ITCL).
  
  
  METHODS
  Polymerase chain reaction for TCR-gamma gene rearrangement, in situ hybridization for EBER1/2 and immunohistochemical staining for CD4, CD8, CD45RO, CD56, TIA-1 were investigated and all patients followed-up. The LMP-1 expression was determined in forty-two ITCLs cases. The relationship between clinical data, different clinicopathological features, expression of EBV genome and prognosis were analyzed by SPSS10.0 program.
  
  
  RESULTS
  (1) All 42 cases of ITCL had an extremely poor prognosis with a median survival of 3.0 months, of which the one year survival rate and two year survival rate being 30% and 22% respectively. (2) The patients without TCR-gamma gene rearrangements showed poorer prognosis than those with TCR-gamma gene rearrangements, and the patients who received operation and chemotherapy showed better prognosis than those who only received operation (P < 0.05). (3) No significant prognostic factor for ITCLs was determined.
  
  
  CONCLUSIONS
  The special clinicopathological features of ITCL could be due to the cytotoxic function and the role of EBV infection in the pathogenesis of ITCL.
authors.affiliation: Department of Pathology, West China Hospital, Sichuan University, Chengdu 610041, China.
authors.forename: Wenyan
authors.initials: W
authors.lastname: Zhang
authors.forename: Gandi
authors.initials: G
authors.lastname: Li
authors.forename: Weiping
authors.initials: W
authors.lastname: Liu
authors.forename: Xingchang
authors.initials: X
authors.lastname: Ren
authors.forename: Huan
authors.initials: H
authors.lastname: Xu
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D005260:Female; D015334:Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor; D006801:Humans; D007414:Intestinal Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D016399:Lymphoma, T-Cell / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D015996:Survival Rate